Atezolizumab and bevacizumab before and after surgery for liver cancer
Part of Cancer clinical trials.
This trial tests whether adding two drugs (atezolizumab and bevacizumab) before and after surgery can lower the chance of liver cancer coming back in people with high-risk HCC. You must be eligible for surgical removal of your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of hepatocellular carcinoma (HCC), the most common liver cancer.
- Your tumor can be completely removed with surgery (R0 resection) and is at high risk of coming back.
- You have not had any prior treatment for HCC (no surgery, chemoembolization, or other therapies).
- Your liver function is good (Child-Pugh Class A) and you have no significant portal hypertension.
- You are willing to provide a tumor biopsy and have adequate blood and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of three drugs given before surgery can help shrink liver cancer and improve outcomes for patients whose tumors can be removed. It is for people with intermediate-stage liver cancer that is still operable.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial studies whether adding atezolizumab and bevacizumab after complete liver cancer surgery can lower the chance the cancer comes back. It also uses “multi-omics” tests (special lab tests on your tissue/blood) to help predict who is more likely to respond or resist treatment.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
Hear when a new Resectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.